Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Vascular and Mixed Dementia
NCT00261573Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 1998
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial in vascular dementia and mixed dementia comparing Galantamine with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale (11 items) at 6 months and Clinician's Interview Based Impression of Change - Plus Caregiver Input at 6 months. Started Dec 1998; status: completed.
02
Drugs
galantamine
03
Conditions
vascular dementiamixed dementia
Beyond the preview
Go deeper on NCT00261573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261573.